Charles Duncan

Stock Analyst at Cantor Fitzgerald

(3.47)
# 945
Out of 5,044 analysts
226
Total ratings
46.01%
Success rate
20.84%
Average return

Stocks Rated by Charles Duncan

COMPASS Pathways
Mar 28, 2025
Reiterates: Overweight
Price Target: n/a
Current: $6.55
Upside: -
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $22.62
Upside: +23.78%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140$150
Current: $138.13
Upside: +8.59%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $133.51
Upside: +14.60%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $14.00
Upside: -
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $57.24
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.20
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.63
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51$58
Current: $29.64
Upside: +95.68%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48$43
Current: $31.00
Upside: +38.71%
Reiterates: Overweight
Price Target: n/a
Current: $61.97
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $10.54
Upside: -
Reiterates: Overweight
Price Target: $155
Current: $147.38
Upside: +5.17%
Reiterates: Overweight
Price Target: n/a
Current: $11.13
Upside: -
Reiterates: Overweight
Price Target: $35
Current: $16.92
Upside: +106.86%
Maintains: Overweight
Price Target: $11$13
Current: $5.58
Upside: +132.97%
Reiterates: Overweight
Price Target: n/a
Current: $7.15
Upside: -
Downgrades: Neutral
Price Target: n/a
Current: $1.59
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $12.87
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $5.96
Upside: -
Reiterates: Overweight
Price Target: $34
Current: $21.36
Upside: +59.18%
Assumes: Overweight
Price Target: $52$50
Current: $42.06
Upside: +18.88%
Initiates: Overweight
Price Target: $5
Current: $5.92
Upside: -15.54%
Reiterates: Overweight
Price Target: $4
Current: $0.35
Upside: +1,057.74%
Reiterates: Overweight
Price Target: $4
Current: $1.27
Upside: +214.96%
Reiterates: Overweight
Price Target: $58
Current: $42.53
Upside: +36.37%
Reiterates: Overweight
Price Target: $1,100
Current: $1.86
Upside: +59,039.78%
Reiterates: Overweight
Price Target: $80
Current: $9.37
Upside: +753.79%
Reiterates: Overweight
Price Target: $3
Current: $1.17
Upside: +156.41%
Downgrades: Neutral
Price Target: $16$11
Current: $8.10
Upside: +35.80%
Upgrades: Overweight
Price Target: $9$12
Current: $8.81
Upside: +36.21%
Maintains: Overweight
Price Target: $146$168
Current: $8.52
Upside: +1,871.83%
Initiates: Overweight
Price Target: $20
Current: $2.36
Upside: +747.46%
Initiates: Overweight
Price Target: $200
Current: $20.89
Upside: +857.40%
Downgrades: Neutral
Price Target: $8$4
Current: $1.49
Upside: +168.46%
Initiates: Overweight
Price Target: $24
Current: $3.58
Upside: +570.39%
Downgrades: Neutral
Price Target: $372$144
Current: $2.58
Upside: +5,481.40%
Maintains: Overweight
Price Target: $3$4
Current: $1.28
Upside: +212.50%
Reiterates: Overweight
Price Target: $35$39
Current: $65.40
Upside: -40.37%
Reiterates: Neutral
Price Target: $14$15
Current: $71.56
Upside: -79.04%
Upgrades: Overweight
Price Target: n/a
Current: $0.59
Upside: -
Initiates: Overweight
Price Target: $180
Current: $4.06
Upside: +4,333.50%